Fate Therapeutics Inc. (Nasdaq: FATE) announced that the first patient has been treated in the DIMENSION study of FATE-NK100 to treat advanced solid tumors. Shares of the biopharmaceutical climbed $1.43 to close at $10.60.
First patient treated with FATE-NK100
February 21, 2018 at 16:44 PM EST